Inhibikase Therapeutics (IKT) Non-Current Assets (2021 - 2026)

Inhibikase Therapeutics (IKT) has reported Non-Current Assets for 6 consecutive years, with $1.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Non-Current Assets rose 891.52% year-over-year to $1.2 million; the TTM figure through Mar 2026 stood at $3.4 million (up 398.23% YoY), while the FY2025 annual figure was $1.1 million, up 637.27% from the prior year.
• Non-Current Assets advanced to $1.2 million in Q1 2026 per IKT's latest filing, from $1.1 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $1.2 million in Q1 2026 and bottomed at $43089.0 in Q2 2022.
• Historically, Non-Current Assets has averaged $439413.5 across 5 years, with a median of $312814.5 in 2023.
• Annual changes were most pronounced in 2025 — Non-Current Assets tumbled 73.84% — and 2026, when it surged 891.52%.
• Inhibikase Therapeutics' Non-Current Assets stood at $565175.0 in 2022, then tumbled by 47.7% to $295599.0 in 2023, then slumped by 49.75% to $148537.0 in 2024, then jumped by 637.27% to $1.1 million in 2025, then advanced by 5.54% to $1.2 million in 2026.
• Business Quant data shows IKT's Non-Current Assets at $1.2 million in Q1 2026, $1.1 million in Q4 2025, and $1.1 million in Q3 2025.